Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 15.19 | -0.22 | -0.76 |
| FCF Yield | -79.43% | -21.03% | -15.62% | -4.46% |
| EV / EBITDA | -1.19 | -3.65 | -4.86 | -21.79 |
| Quality | ||||
| ROIC | -50.28% | -52.26% | -46.57% | -52.28% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.03 | 0.71 | 0.69 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 17.91% | -25.32% | -3.81% | -82.91% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | -0.05 | -0.02 | 0.08 |
| Interest Coverage | 0.00 | 0.00 | -88.27 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.20 | -0.12 |
| Cash Conversion Cycle | -2,079.12 | -3,922.24 | -4,681.01 | -10,754.75 |